Strategic Overview

FY22 marked a transformative year in biomedical research capability. The emphasis shifted toward advanced human-relevant testing models to improve pre-clinical predictability and reduce development gaps.

Human Organ-on-a-Chip Installation

For the first time in India, a Human Organ-on-a-Chip laboratory was installed.

Key highlights:

• Kidney-on-a-chip microfluidic 3D system
  
• Simulation of human physiological responses
  
• Improved drug toxicity screening accuracy
  
• Foundation for multi-organ tandem flow models
  

This miniature system enabled deeper insight into mechanisms of kidney damage and therapeutic response.

Research Collaborations

Key collaborations established:

• Newcells Biotech (UK)
  
• CDRI-CSIR (India)
  
• NortisBio (US)
  
• Pharma-Stats (India)
  
• Cliantha (India)
  

These partnerships supported experimentation, training, clinical execution, and statistical consulting.

Scientific Engagement

• Research posters presented at major global forums including World Microbe Forum and ECCMID.
  

Pipeline & IP Growth

• VRP-034 progressed within Renal Guard platform
  
• VRT-001 and additional molecules under development
  
• R3SET launched in pain management segment
  
• 350+ patents filed
  
• 100+ patents granted & trademarks registered
• 25+ trademarks
  

FY22 strengthened scientific foundations and positioned research capability at a new technological frontier.